drug repurposing

Aerys Biosciences is a clinical-stage biopharmaceutical company headquartered in Stanford Research Park, Palo Alto, California, spun out of Stanford University and Greenstone Biosciences. It develops next-generation small-molecule therapies for fibro-inflammatory lung diseases, including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH), targeting mechanisms driving fibrosis and vascular remodeling.

early-stage clinical trialshIPSC-based disease modelshuman-relevant drug discoverypreclinical and translational studiessmall molecule therapeutic development

Caren Pharma develops hormone-based therapeutics for age-related diseases, reformulating clinically validated agents into novel treatments targeting the biological drivers of cognitive decline. Its lead program combines two FDA-approved drugs repurposed to address age-related memory loss, aiming to reach patients faster and more effectively.

drug reformulationtherapeutic development

Chemotargets is a Barcelona-based company that collects and learns from biomedical data to advance drug discovery and development. It offers the SafetySuite collection of data, signals and analytics products (SafetyOne, SafetySignals, SafetyStrata, SafetyVista) and CLARITY, a software platform for predictive off-target pharmacology and safety of small molecules. It also provides drug safety, repurposing and discovery services, and has a multidisciplinary team of more than 30 computational biologists, chemists, data scientists and software developers.

ADME predictioncomputational drug designde novo design and scaffold hoppingmachine learning-aided drug designmolecular dynamics simulationspharmacovigilance analyticspredictive pharmacology and safetyvirtual fragment-based screening

CMTx Biotech, Inc. is a Stony Brook, NY company developing medical countermeasures against high priority CBRN threats. It pursues drug rescue and repositioning, including new therapeutic uses and formulations of clinical stage drug candidates and of drugs already approved for human use. Its science focuses on host-directed therapeutics (HDTs) targeting hyper-inflammatory and dysregulated immune responses to infection, insult, or injury. Lead candidate incyclinide has completed IND-enabling studies; CMTx R2 is an STS protein inhibitor advanced for host-di

drug developmenthost-directed therapeuticsIND-enabling studiesmanufacturingtechnology commercialization and licensing